Advanced search
Publication Cover
Hematology Volume 15, 2010 - Issue 2
Submit an article Journal homepage
278
Views
14
CrossRef citations to date
0
Altmetric
Hematological Malignancy: Current Clinical Guidelines

Rapid control of previously untreated multiple myeloma with bortezomib–lenalidomide–dexamethasone (BLD)

M. WangDepartment of Lymphoma and MyelomaUniversity of Texas M.D. Anderson Cancer Center, Houston, TX77030, USA
,
K. DelasalleDepartment of Lymphoma and MyelomaUniversity of Texas M.D. Anderson Cancer Center, Houston, TX77030, USA
,
S. GiraltDepartment of Lymphoma and MyelomaUniversity of Texas M.D. Anderson Cancer Center, Houston, TX77030, USA
&
R. AlexanianDepartment of Lymphoma and MyelomaUniversity of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 429, Houston, TX77030-4009, USA. [email protected]
Pages 70-73 | Published online: 18 Jul 2013

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Hang Quach, H Miles Prince & Andrew Spencer. (2011) Managing multiple myeloma in the elderly: are we making progress?. Expert Review of Hematology 4:3, pages 301-315.
Read now

Articles from other publishers (13)

Shaji K. Kumar, Jacob P. Laubach, Thomas J. Giove, Maureen Quick, Rachel Neuwirth, Godwin Yung, S. Vincent Rajkumar & Paul G. Richardson. (2017) Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma. British Journal of Haematology 178:5, pages 756-763.
Crossref
Pieter SonneveldEmilie AsselbergsSonja ZweegmanBronno van der HoltMarie Jose KerstenEdo VellengaMarinus van Marwijk-KooyAnnemiek BroylOkke de WeerdtSarah LonerganAntonio Palumbo & Henk Lokhorst. (2015) Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. Blood 125:3, pages 449-456.
Crossref
Shenghao Wu, Cuiping Zheng, Songyan Chen, Xiaoping Cai, Yuejian Shi, Bijing Lin & Yuemiao Chen. (2015) Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients. BioMed Research International 2015, pages 1-6.
Crossref
Paul G. RichardsonWanling XieSundar JagannathAndrzej JakubowiakSagar LonialNoopur S. RajeMelissa AlsinaIrene M. GhobrialRobert L. SchlossmanNikhil C. MunshiAmitabha MazumderDavid H. VesoleJonathan L. KaufmanKathleen ColsonMary McKenneyLaura E. LundeJohn FeatherMichelle E. MaglioDiane WarrenDixil FrancisTeru HideshimaRobert Knight, Dixie-Lee Esseltine, Constantine S. MitsiadesEdie WellerKenneth C. Anderson. (2014) A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood 123:10, pages 1461-1469.
Crossref
R Alexanian, M Wang, K Delasalle, S Wang, M Qazilbash, B Handy & D Weber. (2013) Value of novel agents and intensive therapy for patients with multiple myeloma. Bone Marrow Transplantation 49:3, pages 422-425.
Crossref
Raymond Alexanian, Kay Delasalle & Michael Wang. (2013) High Frequencies of Response After Limited Primary Therapy for Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 13:2, pages 119-122.
Crossref
Weijun Fu, Kay Delasalle, Jialei Wang, Shen Song, Jian Hou, Raymond Alexanian & Michael Wang. (2012) Bortezomib-Cyclophosphamide-Dexamethasone for Relapsing Multiple Myeloma. American Journal of Clinical Oncology 35:6, pages 562-565.
Crossref
Philippe Moreau & Sergio A. Giralt. (2012) Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma. Leukemia Research 36, pages S13-S18.
Crossref
Andrzej J. JakubowiakDominik DytfeldKent A. GriffithDaniel LebovicDavid H. VesoleSundar Jagannath, Ammar Al-ZoubiTara AndersonBrian NordgrenKristen Detweiler-ShortKeith Stockerl-Goldstein, Asra AhmedTerri JobkarDiane E. DureckiKathryn McDonnellMelissa MietzelDaniel CourielMark KaminskiRavi Vij. (2012) A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 120:9, pages 1801-1809.
Crossref
J R Berenson, O Yellin, T Kazamel, J D Hilger, C-S Chen, A Cartmell, T Woliver, M Flam, E Bravin, Y Nassir, R Vescio & R A Swift. (2012) A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma. Leukemia 26:7, pages 1675-1680.
Crossref
Raymond Alexanian, Kay Delasalle, Michael Wang, Sheeba Thomas & Donna Weber. (2012) Curability of Multiple Myeloma. Bone Marrow Research 2012, pages 1-5.
Crossref
Andrzej J. JakubowiakKent A. GriffithDonna E. ReeceCraig C. HofmeisterSagar LonialTodd M. ZimmermanErica L. CampagnaroRobert L. SchlossmanJacob P. LaubachNoopur S. RajeTara AndersonMelissa A. MietzelColleen K. HarveySandra M. WearJennifer C. BarrickmanCraig L. Tendler, Dixie-Lee Esseltine, Susan L. KelleyMark S. KaminskiKenneth C. AndersonPaul G. Richardson. (2011) Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. Blood 118:3, pages 535-543.
Crossref
Michele CavoS. Vincent RajkumarAntonio PalumboPhilippe MoreauRobert OrlowskiJoan BladéOrhan SezerHeinz LudwigMeletios A. DimopoulosMichel AttalPieter SonneveldMario BoccadoroKenneth C. AndersonPaul G. RichardsonWilliam BensingerHans E. JohnsenNicolaus KroegerGösta GahrtonP. Leif BergsagelDavid H. VesoleHermann EinseleSundar JagannathRuben NiesvizkyBrian G. M. DurieJesus San Miguel & Sagar Lonial. (2011) International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 117:23, pages 6063-6073.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.